Bolt Biotherapeutics, Inc. (BOLT)
BOLT Stock Price Chart
Explore Bolt Biotherapeutics, Inc. interactive price chart. Choose custom timeframes to analyze BOLT price movements and trends.
BOLT Company Profile
Discover essential business fundamentals and corporate details for Bolt Biotherapeutics, Inc. (BOLT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
5 Feb 2021
Employees
52.00
Website
https://www.boltbio.comCEO
William Quinn
Description
Bolt Biotherapeutics, Inc. is a biotechnology company currently conducting clinical trials, focused on developing innovative immuno-oncology therapies. Its mission is to create agents that equip the body's immune system to identify and eliminate cancerous cells. A key therapeutic in its pipeline is BDC-1001, an investigational treatment targeting the human epidermal growth factor receptor 2 (HER2). This compound is presently undergoing Phase I/II clinical evaluation for patients with HER2-positive solid tumors, including those exhibiting low HER2 expression. Beyond BDC-1001, the company is advancing several other programs: BDC-2034, which targets carcinoembryonic antigen for various indications such as colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody designed to reprogram crucial immune cells within the tumor microenvironment by interacting with macrophage cell-surface receptors. Bolt is also pursuing a programmed cell death-ligand 1 (PD-L1) initiative aimed at addressing tumors that prove resistant to existing immune checkpoint blockades. Incorporated in 2015 under its previous name, Bolt Therapeutics, Inc., before officially becoming Bolt Biotherapeutics, Inc. in July of the same year, the company maintains its corporate headquarters in Redwood City, California.
BOLT Financial Timeline
Browse a chronological timeline of Bolt Biotherapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Aug 2026
EPS estimate is -$3.39, while revenue estimate is $500.00k.
Earnings released on 12 May 2026
EPS came in at -$4.31 falling short of the estimated -$2.85 by -51.23%, while revenue for the quarter reached $26.00k , missing expectations by -98.27%.
Earnings released on 12 Mar 2026
EPS came in at -$3.84 surpassing the estimated -$4.30 by +10.70%, while revenue for the quarter reached $2.50m , beating expectations by +275.00%.
Earnings released on 12 Nov 2025
EPS came in at -$3.72 surpassing the estimated -$5.07 by +26.63%, while revenue for the quarter reached $2.17m , beating expectations by +164.25%.
Earnings released on 14 Aug 2025
EPS came in at -$4.46 surpassing the estimated -$6.40 by +30.31%, while revenue for the quarter reached $1.80m , beating expectations by +113.29%.
Stock split effective on 9 Jun 2025
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 12 May 2025
EPS came in at -$5.80 surpassing the estimated -$6.80 by +14.71%, while revenue for the quarter reached $1.22m , beating expectations by +59.22%.
Earnings released on 24 Mar 2025
EPS came in at -$7.60 matching the estimated -$7.60, while revenue for the quarter reached $10.00k , missing expectations by -98.73%.
Earnings released on 12 Nov 2024
EPS came in at -$0.40 falling short of the estimated -$0.36 by -11.11%, while revenue for the quarter reached $1.14m , beating expectations by +44.43%.
Earnings released on 13 Aug 2024
EPS came in at -$0.56 falling short of the estimated -$0.54 by -3.70%, while revenue for the quarter reached $1.28m , beating expectations by +43.26%.
Earnings released on 14 May 2024
EPS came in at -$0.28 surpassing the estimated -$0.51 by +45.10%, while revenue for the quarter reached $5.27m , beating expectations by +156.02%.
Earnings released on 21 Mar 2024
EPS came in at -$0.47 matching the estimated -$0.47, while revenue for the quarter reached $2.09m , beating expectations by +21.96%.
Earnings released on 9 Nov 2023
EPS came in at -$0.43 surpassing the estimated -$0.49 by +12.24%, while revenue for the quarter reached $2.53m , beating expectations by +42.82%.
Earnings released on 7 Aug 2023
EPS came in at -$0.48 surpassing the estimated -$0.53 by +9.43%, while revenue for the quarter reached $1.43m , missing expectations by -24.58%.
Earnings released on 11 May 2023
EPS came in at -$0.45 surpassing the estimated -$0.49 by +8.16%, while revenue for the quarter reached $1.83m , beating expectations by +39.39%.
Earnings released on 29 Mar 2023
EPS came in at -$0.53 surpassing the estimated -$0.63 by +15.87%, while revenue for the quarter reached $1.41m , beating expectations by +14.25%.
Earnings released on 10 Nov 2022
EPS came in at -$0.58 falling short of the estimated -$0.56 by -3.57%, while revenue for the quarter reached $2.11m , beating expectations by +71.71%.
Earnings released on 10 Aug 2022
EPS came in at -$0.61 surpassing the estimated -$0.68 by +10.29%, while revenue for the quarter reached $1.39m , beating expectations by +178.60%.
Earnings released on 12 May 2022
EPS came in at -$0.64 surpassing the estimated -$0.71 by +9.86%, while revenue for the quarter reached $813.00k , beating expectations by +62.60%.
Earnings released on 30 Mar 2022
EPS came in at -$0.73 falling short of the estimated -$0.66 by -10.61%, while revenue for the quarter reached $508.00k , beating expectations by +35.47%.
Earnings released on 9 Nov 2021
EPS came in at -$0.63 matching the estimated -$0.63, while revenue for the quarter reached $752.00k , beating expectations by +50.40%.
Earnings released on 12 Aug 2021
EPS came in at -$0.64 falling short of the estimated -$0.38 by -68.42%.
BOLT Stock Performance
Access detailed BOLT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
